- The disease
- Variegate porphyria is a rare inherited metabolic disorder caused by a deficiency of the enzyme protoporphyrinogen oxidase, resulting in the accumulation of porphyrin precursors. Patients experience acute neurovisceral attacks and, in many cases, severe cutaneous photosensitivity that causes blistering, scarring, and pain upon exposure to sunlight. The condition is classified as an acute hepatic porphyria with a cutaneous component, distinguishing it from purely cutaneous porphyrias such as erythropoietic protoporphyria (EPP). There is currently no approved pharmacological therapy specifically indicated for the cutaneous photosensitivity component of VP.
- What the asset is trying to do
- SCENESSE (afamelanotide) is a synthetic analogue of alpha-melanocyte stimulating hormone (alpha-MSH) that acts as an agonist at the melanocortin 1 receptor (MC1R). Binding to MC1R stimulates melanin production in the skin, increasing the skin's natural photoprotective pigmentation. This mechanism is intended to reduce the phototoxic skin damage that occurs in VP patients when porphyrins accumulate and react with light. Afamelanotide is delivered as a subcutaneous biodegradable implant, distinguishing it from topical or oral photoprotective agents.
- What the trial is measuring, and why it matters
- The completed Phase 2 study (NCT05854784) evaluated the safety and efficacy of afamelanotide 16 mg in patients with VP, with a primary completion date of 28 December 2023 (per ClinicalTrials.gov NCT05854784). The trial enrolled a target of six patients, consistent with a small proof-of-concept study design in an ultra-rare disease. Clinuvel has noted the Phase 2 was completed with positive efficacy results, though the specific endpoints and outcome data have not been fully disclosed in the inputs available here. .
- Efficacy benchmarks in this setting
- No therapy is currently approved specifically for the cutaneous photosensitivity of variegate porphyria, so there is no approved-comparator benchmark with published response rates for this exact indication. In the related condition EPP, afamelanotide (SCENESSE) is approved in the European Union and the United States; the pivotal EU trial reported a statistically significant increase in time spent in sunlight without pain versus placebo (Langendonk et al, New England Journal of Medicine, 2015). Afamelanotide is also approved in the EU for EPP, supported by data showing a median increase in pain-free direct sun exposure time (Langendonk et al, NEJM 2015). Because the VP Phase 2 enrolled only six patients (per ClinicalTrials.gov NCT05854784), any efficacy figures from that study are not statistically comparable to data from larger, controlled trials in other indications.